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Skeletal muscle mRNA for IGF-IEa, IGF-II, and IGF-I recep-
tor is decreased in sedentary chronic hemodialysis patients.
Background. Maintenance hemodialysis patients often dis-
play evidence for protein-energy malnutrition, inflammation,
and sarcopenia. We therefore investigated whether sedentary
maintenance hemodialysis patients have decreased skeletal
muscle mRNA levels and muscle and serum protein concen-
trations of certain growth factors.
Methods. Fifty-one clinically stable maintenance hemodialy-
sis patients (32 men and 19 women), and 21 normal adults (16
men and five women) of similar age, gender mix, racial/ethnic
backgrounds, serum albumin, body composition, and level of
sedentary activity were studied. Individuals underwent biopsy
of the right vastus lateralis muscle, and real-time polymerase
chain reaction (PCR) amplification of mRNAs for insulin-like
growth factor-I (IGF-I), IGF-II, IGF-I receptor (IGF-IR), IGF-
IIR, and myostatin (44 patients) was performed. Serum and
muscle IGF-I and IGF-II, serum proinflammatory cytokines,
and leg muscle strength, power, and fatigability were measured.
Results. Maintenance hemodialysis patients displayed signif-
icantly reduced mRNA levels for IGF-IEa mRNA (P < 0.05),
IGF-II (P < 0.001), and IGF-IR (P < 0.001), and no difference
in mRNAs for IGF-IEc, IGF-IIR, or myostatin as compared
to normal controls. Muscle mRNA levels, in general, followed
the same pattern in male and female maintenance hemodialysis
patients considered separately. In the maintenance hemodial-
ysis patients, muscle IGF-I protein, serum IGF-II and tumor
necrosis factor-a (TNF-a) were each increased, whereas serum
C-reactive protein (CRP) and interleukin-6 (IL-6) were normal.
Muscle strength and power, but not fatigability, were reduced
in the maintenance hemodialysis patients.
Conclusion. In sedentary, clinically stable maintenance
hemodialysis patients as compared to sedentary normal indi-
viduals, the mRNA levels for IGF-IEa, IGF-II, and the IGF-I
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receptor are decreased in vastus lateralis muscle. Protein levels
for muscle IGF-I and serum IGF-II are increased.
Individuals with end-stage renal disease (ESRD), in-
cluding those undergoing maintenance dialysis, often
have protein energy malnutrition [1] and an inflammatory
state [2]. These conditions may promote a catabolic or an-
tianabolic state leading to a reduction in skeletal muscle
protein and sarcopenia. Indeed, reduced noncollagenous
alkali-soluble protein has been described in skeletal mus-
cle of both adults and children with advanced chronic
renal failure (CRF) [3, 4], and maintenance hemodial-
ysis patients are often sarcopenic [5–7]. The quantity of
growth factors expressed in muscle tissue is a determinant
of protein synthesis and degradation and hypertrophy of
skeletal muscle [8–10]. The degree of expression of such
proteins, in turn, is dependent on the magnitude of gene
expression or transcription of the genes encoding these
proteins.
As part of an investigation of the potential causes
of sarcopenia in individuals with ESRD, we examined
the mRNA levels for such growth factors as insulin-like
growth factor-I (IGF-I), both the splice variants, IGF-
IEa and IGF-IEc, and IGF-II, their receptors (IGF-IR
and IGF-IIR), and myostatin in skeletal muscle of clin-
ically stable, sedentary maintenance hemodialysis pa-
tients. Serum and skeletal muscle levels of the IGF-I
and IGF-II proteins as well as serum levels of certain
proinflammatory cytokines, and leg muscle function were
also measured. Normal sedentary individuals of similar
age, gender distribution, and racial/ethnic backgrounds
served as controls.
METHODS
This study was carried out in 51 patients, 32 men
and 19 women, who had been undergoing maintenance
hemodialysis for a mean of 54.7 months (range 6 to 297
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months) and 21 normal control subjects, 16 men and
five women. The maintenance hemodialysis patients were
participants in a clinical trial to examine the physiologic
and metabolic responses to exercise training. The mus-
cle biopsies on which this study is based were performed
before the initiation of the exercise training intervention.
Normal controls were selected on the basis of having no
chronic illnesses or acute inflammatory processes. An in-
clusion requirement for participation in this study was
that each maintenance hemodialysis patient and normal
control give a history of not engaging in recent manual
labor or exercise training. Although it could not be deter-
mined with certainty that the normal individuals were as
physically inactive as the maintenance hemodialysis pa-
tients, none of the maintenance hemodialysis patients or
normal controls described participation in regular physi-
cal exercise or frequent sports activities.
Maintenance hemodialysis patients frequently sustain
intercurrent illnesses or suffer from severe comorbidity
[11] which could affect the results of this study. Hence,
in order to examine the status of ESRD patients under-
going maintenance hemodialysis rather than the poten-
tial effects of complicating illnesses, only clinically stable
maintenance hemodialysis patients who had volunteered
and been accepted for participation in an exercise training
program were evaluated. The maintenance hemodialysis
patients did not have evidence of acute or chronic inflam-
matory diseases, severe heart, lung or liver failure, muscle
diseases, any joint infirmity that would prevent them from
exercising their lower extremities, or abuse of alcohol or
other drugs. One woman and four men receiving main-
tenance hemodialysis had noninsulin-requiring diabetes
mellitus.
The normal subjects had normal serum creatinine con-
centrations, and none had a history of kidney disease
or hypertension. None of the maintenance hemodialy-
sis patients or normal individuals manifested evidence of
coronary artery ischemia during an exercise electrocar-
diogram. The dorsal pedal artery:brachial artery blood
pressure ratio was 0.90 or greater in all maintenance
hemodialysis patients and normal subjects. This study was
approved by the Human Subjects Committee at Harbor-
UCLA Medical Center, and informed written consent
was obtained from all subjects.
Skeletal muscle biopsy
Biopsies were performed on the right vastus lateralis
muscle about 10 cm cephalad to the superior border of
the patella, 1 to 2 cm anterior to the midlateral line of the
right leg. A Bergstrom or U.C.H. skeletal muscle biopsy
needle (Popper & Sons, Inc., New Hyde Park, NY, USA)
was used. All subjects were fasted from 10:00 p.m. the
night before biopsy, except occasionally for a small glass
of water imbibed the morning of the biopsy. Maintenance
hemodialysis patients were biopsied in the midweek, 1
day after a hemodialysis treatment.
RNA extraction
Blood was blotted off the tissue, and fat and connective
tissue were quickly dissected away from the skeletal mus-
cle which was then placed immediately in liquid nitrogen.
At the time of analysis, the frozen tissue was homogenized
in TRIzol Reagent using a power homogenizer (Power-
Gen) (Fisher Scientific, Pittsburgh, PA, USA) as previ-
ously described [12]. The homogenate was incubated for
5 minutes at room temperature; chloroform was added;
the sample was shaken vigorously for 15 seconds, and in-
cubated at 15 to 30◦C for 2 to 3 minutes. The mixture was
separated into two phases by centrifuging at 12,000 rpm
for 15 minutes at 4◦C. RNA was precipitated from the
aqueous phase by mixing with isopropanol. The sample
was incubated at 15 to 30◦C and centrifuged at 12,000 rpm
at 4◦C. The pellet was washed twice with 75% ethanol and
centrifuged at no more than 7500 × g for 5 minutes at 4◦C.
Any remaining ethanol was removed. The RNA was dis-
solved in RNase free water and incubated for 10 minutes
at 55 to 60◦C. The concentration of RNA was measured
with a spectrophotometer (Beckman DU 640, Fullerton,
CA, USA).
Reverse-transcriptase (RT) reaction
cDNA synthesis was accomplished with 1 lg RNA;
the final reaction mixture contained 1 lg total RNA,
10 units RNase inhibitor, 1 mmol/L each deoxynucleo-
side triphosphate (dNTP), 3.2 lg random primer p[dN]6,
avian myeloblastosis virus (AMV) Reverse Transcrip-
tase 20 U and RNase free water, in a final volume of
20 lL of buffer as described in the manufacturer’s proto-
col (Roche Applied Science, Indianapolis, IN, USA). The
reaction was allowed to proceed for 10 minutes at 25◦C,
1 hour at 42◦C, and was then terminated after 5 minutes
at 99◦C.
Real-time polymerase chain reaction (PCR)
amplification of mRNAs for IGF-IEa and IGF-IEc,
IGF-II, IGF-IR, IGF-IIR, and myostatin
For real-time PCR, the ABI Prism Sequence Detec-
tion System 7000 was used (Applied Biosystems Inc.,
Foster City, CA, USA). Specific primers were designed
using the m-fold and Primer-3 Web-based programs,
to amplify the mRNA from reverse transcribed cDNA
for IGF-I, IGF-II, IGF-1R, IGF-IIR, and myostatin
with the following oligonucleotides: IGF-IEa forward,
5′-CTTCCGGAGCTGTGATCTA-3′, and reverse,
5′-TGCGTTCTTCAAATGTACTTC-3′; IGF-IEc for-
ward, 5′-CGAAGTCTCAGAGAAGGAAAGG-3′, and
reverse, 5′-ACAGGTAACTCGTGCAGAGC-3′; IGF-
II forward, 5′-CCTGGAGACGTACTGTGCTA-3′, and
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reverse 5′-GGACTGCTTCCAGGTGTC-3′; IGF-IR
forward, 5′-CTGCTGATGTGTACGTTCCT-3′, and
reverse, 5′-TCAGGTTCATCTTTCACCAC-3′; IGF-IIR
forward, 5′-GCTGTTTGTATGCACGACTT-3′, and
reverse, 5′-TGCTCTGGACTCTGTGATTT-3′; myo-
statin forward, 5′-GGAAACAATCATTACCATGC-3′
and reverse, 5′-ATCCATAGTTGGGCCTTTAC-3′; and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
forward, 5′-ATCACTGCCACCCAGAAGACT-3′, and
reverse, 5′-CATGCCAGTGAGCTTCCCGTT-3′.
Primers were designed to include an intron in the PCR
product to distinguish between genomic DNA contam-
ination and cDNA. The primer concentration was cho-
sen without primer dimer formation. The primers for
IGF-I mRNA specifically replicated the mRNA isoform
for IGF-IEa [13] or IGF-IEc [14]. Fifty microliters re-
actions were set up containing 2 lL of cDNA, 25 lL
2 × SYBR Green PCR Master Mix (Qiagen, Inc., Va-
lencia, CA, USA), and 0.5 lmol/L of each specific sense
and antisense primer. PCR parameters for amplification
were as follows: incubation for 2 minutes at 50◦C, initial
denaturation for 10 minutes at 95◦C, followed by 40 cy-
cles of 15 seconds at 95◦C, and 1 minute at 56◦C. Each
sample was analyzed in duplicate. Quality control was
performed with melting curve analysis and amplified
products were electrophoresed on 2% agarose gel and
stained with ethidium bromide to obtain only one spe-
cific band with correct size.
Gene expression for GAPDH was assayed as an inter-
nal control (done in parallel for each experiment, not in
the same sample well). For quantification we used Rela-
tive Quantification with External Standards (Roche Ap-
plied Science). Standard curves representing five-point
serial dilutions of known amounts of cDNA were ana-
lyzed in each assay. A known amount of cDNA was used
as a calibrator in each assay. Standard curves were used
in the relative quantification of the product generated in
the early exponential phase of the amplification curve.
The r2 was greater than 0.99 for all standard curves, and
amplification efficiency varied between 85% and 100%.
Sample quantification was calculated from the standard
curve. Duplicates were averaged and normalized by di-
viding by the internal control GAPDH mRNA in all of
the experiments.
Protein assay for muscle IGF-I and IGF-II
The muscle sample was weighed and homogenized in
acid/ethanol solution (12.5% 2 N HCl/87.5% ethanol)
at a concentration of 20 lL per mg muscle (PowerGen
Homogenizer 125) (Fisher Scientific). The acid/ethanol
extraction was used to separate IGF-I and IGF-II from
their binding proteins [15]. The homogenate was then in-
cubated for 1 hour at 4◦C followed by centrifugation at
3000g at 4◦C for 30 minutes. The resultant supernatant
was decanted and neutralized with 0.855 mol/L Tris base.
The neutralized supernatant was incubated overnight at
−20◦C and then centrifuged at 3000g at 4◦C for 30 min-
utes. The final supernatant was stored at −80◦C for de-
termination of IGF-I and IGF-II by radioimmunoassay
(RIA).
Muscle IGF-I and IGF-II were measured as fol-
lows. The DSL-5600 immunoradiometric assay (IRMA)
Kit (Diagnostic System Laboratories, Inc. Webster, TX,
USA) was used for the IGF-I assay. Fifty microliters of
reconstituted standards, controls, and supernatants ex-
tracted from the muscle of the subjects were added to
the appropriate tubes; then 200 lL of anti-IGF-I (125I-
labeled) were added to all tubes. Duplicate tubes were
prepared for each specimen, including standards and con-
trols. All tubes were then incubated at room temperature
for 3 hours on a shaker set at 180 rpm. Except for the to-
tal count tubes, all of the tubes were decanted and then
washed three times. All tubes were counted for radioac-
tivity in a gamma counter for 1 minute. Net counts per
minute for standards, unknowns, and controls in dupli-
cate tubes were averaged, and nonspecific binding was
subtracted. A linear regression analysis of the net counts
per minute from five IGF-I standards was used to calcu-
late the unknown IGF-I concentration. The IGF-II assay
followed a similar procedure as specified in the DSL-2600
Kit.
Protein assay for serum IGF-I and IGF-II
Nine hundred microliters of acid-ethanol solution
(12.5%/87.5% vol/vol) were added to 100 lL of the sam-
ple sera. The mixtures were vortexed and incubated at
room temperature for 30 minutes and then centrifuged
at 3000g at 4◦C for 30 minutes. After centrifugation, 200
lL of supernatants were transferred to the corresponding
tubes; then 0.1 mL of Tris base solutions were added to
the supernatant. The mixtures were vortexed thoroughly
and incubated for 30 minutes at room temperature, then
centrifuged at 3000g at 4◦C for 30 minutes. After cen-
trifugation, 100 lL supernatants were transferred to the
tubes containing 1.4 mL phosphate dilution buffer, the fi-
nal dilution of the sample was 1 to 225. The samples were
mixed thoroughly and underwent the RIA. Extraction
for the serum IGF-II assay followed a similar procedure
as specified in the DSL-2600 Kit.
Serum IGF-I and IGF-II were measured as fol-
lows. Nichols Institute Diagnostics IGF-I 100T Kit (San
Clemente, CA, USA) was used for the serum IGF-I as-
say. Except for the total count tubes, 150 lL of standards,
extracted controls and samples were added to the corre-
sponding tubes; then 250 lL of phosphate buffer were
added to nonspecific binding tubes and 150 lL of phos-
phate buffer were added to the other tubes. Except for
the total count and nonspecific binding tubes, 100 lL
IGF-I antibodies from rabbit were added to all tubes;
the mixtures was vortexed and then incubated at room
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temperature for 1 hour. One hundred microliters of IGF-
I antibodies (125I-labeled) were added to all tubes. Except
for the total count tubes, all tubes were vortexed and in-
cubated at 4◦C for 18 hours; 500 lL of cold and gently
mixed antirabbit precipitants was added. Then 50 lL of
normal rabbit serum were added to the tubes. All tubes
were vortexed and incubated for 20 minutes at room tem-
perature. All tubes, except for the total column tubes,
were centrifuged at 3000g at 4◦C for 30 minutes and then
decanted. All tubes were counted, and results were cal-
culated. The serum IGF-II assay followed the same pro-
cedure as specified in the DSL-2600 Kit.
C-reactive protein (CRP) assay
The Wako Diagnostics (Richmond, VA, USA) CRP-
UL Kit was used for the CRP assay. It is based on latex
immunoassay. The Hitachi 704 analyzer was used for this
assay.
Interleukin-6 (IL-6) and tumor necrosis factor-a
(TNF-a) assay
The R&D Systems (Minneapolis, MN, USA) IL-6 Kit
was used for the IL-6 assay. One hundred microliters of
assay diluent and 100 lL of standard or sample were
added to each well; the plate was incubated for 2 hours
at room temperature on a microplate shaker at 500 rpm.
The wells were washed six times. Two hundred microliters
of IL-6 conjugate were added to each well, incubated for
2 hours at room temperature on the shaker, and then
washed again. Fifty microliters of substrate solution were
added to each well and incubated for 1 hour at room tem-
perature. Then 50 lL of amplifier solution were added to
each well and incubated for 30 minutes. Then 50 lL of
stop solution were added to each well. The optical den-
sity was determined using a microplate reader at 490 nm;
650 nm reading was used for correction. The TNF-a assay
followed a similar procedure as specified in R&D Systems
TNF-a Kit.
Nutrient intake, clinical laboratory measurements,
and anthropometry
Nutrient intake was determined at the time of the
muscle biopsy from 3-day dietary diaries and dietary
interviews conducted by research dieticians in the
Harbor-UCLA General Clinical Research Center. Serum
for assays of IGF-I, IGF-II, CRP, IL-6, and TNF-a were
obtained at the time of the muscle biopsy. Other serum
and whole blood values reported here were measured in
blood obtained immediately before the onset of a mid-
week hemodialysis. Measurements of serum urea nitro-
gen (SUN), creatinine, bicarbonate and albumin, and the
hemoglobin and hematocrit were performed using stan-
dard clinical laboratory techniques.
Body weight, height, biceps, triceps, subscapular and
mid-calf skinfold thickness, and mid-arm, mid-thigh, and
mid-calf circumferences were measured by experienced
Harbor-UCLA General Clinical Research Center re-
search nutritionists as previously described [16]. Body
mass index and mid-arm muscle circumference were as-
sessed as previously reported [16]. Mid-arm muscle cir-
cumference was calculated from the following equation:
Mid-arm muscle circumference
= mid-arm circumference
− [0.31415927 × triceps skinfold (cm)]
Mid-thigh and mid-calf circumferences were measured
at the point of largest cross-sectional area of the thigh
and calf, respectively. Mid-thigh muscle circumference
and mid-calf muscle circumference were calculated from
the following equations:
Mid thigh muscle cicumference
= mid - thigh circumference
− [0.31415927(p ) × mid-thigh skinfold (cm)]
and
Mid-calf muscle circumference
= mid-calf circumference
− [p × mid-calf skinfold (cm)]
Total body fat was calculated from the equations of
Durnin and Wormersley [17]:
Body fat (% of weight)
= [(4.95/body density) − 4.5] × 100
Body density was calculated from the equation:
Body density (kg/m3) = K1 − [K2 × log10 SK4 (mm)]
where K1 and K2 are constants specific for a given gender
and age range of normal people [17] and SK4 refers to the
sum of the thicknesses of the biceps, triceps, subscapular,
and suprailiac skinfolds.
Leg muscle function
Quadriceps strength was assessed with a seated leg
press exercise instrument (Keiser Sport, Fresno, CA,
USA) using the five repetition maximum technique [18]
rather than the single repetition method. Knee and hip
extension power (rate of generating force) was assessed
with a validated leg power instrument (University of
Nottingham Medical College, Nottingham, UK) [19].
Fatigability (the ability to make repetitive submaximal
dynamic contractions) was assessed with the same bilat-
eral leg press exercise used in strength testing.
Statistical analyses
Data are expressed as the mean value ± SD or range
of values. Statistical comparisons were performed by the
unpaired t test and by linear regression analyses. For
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Table 1. Characteristics of subjects
Maintenance
hemodialysis Normal
patients subjects P value
Number M/F 32/19 16/5
Racial/ethnic background
African American M/F 10/10 3/2
Hispanic M/F 16/8 10/2
Caucasian M/F 1/0 1/1
Philipino M/F 4/0 2/0
Asian M/F 0/1 0/0
Other M/F 1/0 0/0
Age years 42.1 ± 11.4a 40.9 ± 12.4 NS
Duration of hemodialysis months 54.7 ± 66.2 —
Diabetes mellitus M/F 4/1 0/0
Serum or blood
Creatinine mg/dL 9.6 ± 3.3 0.9 ± 0.2 <0.001
Urea nitrogen mg/dL 37.6 ± 14.1 9.5 ± 3.2 <0.001
Bicarbonate mEq/L 30.8 ± 3.8 28.9 ± 3.0 <0.05
Albumin g/dL 3.8 ± 0.3 3.9 ± 0.4 NS
Hemoglobin g/dL 13.0 ± 1.3 14.3 ± 1.0 <0.001
Hematocrit, vol% 39.0 ± 3.8 41.7 ± 3.1 0.004
aMean ± SD.
Serum and blood values in maintenance hemodialysis patients patients were
obtained the day after a usual hemodialysis treatment.
comparison of values between groups, a statistically sig-
nificant difference was taken as P < 0.05. Since many
linear regression analyses were performed, only associa-
tions with a regression coefficient greater than 0.30 are
reported.
RESULTS
Characteristics of the maintenance hemodialysis pa-
tients and normal controls are shown in Table 1. More
men than women were present in both the mainte-
nance hemodialysis patient and normal control groups,
and most of the maintenance hemodialysis patients and
normals were either African American or non-African
American Hispanic. The mean age and serum albu-
min concentrations were similar in the two groups,
whereas serum bicarbonate was slightly higher and the
hemoglobin and hematocrit were slightly lower in the
maintenance hemodialysis patients.
Dietary energy and protein intakes, expressed in
kcal/day and g protein/day, were each decreased in male
maintenance hemodialysis patients as compared to nor-
mal men (Table 2). Protein intake in male and female
maintenance hemodialysis patients combined, expressed
as g protein/day, were also lower than in the normal sub-
jects. On the other hand, dietary energy or protein intake
in the female maintenance hemodialysis patients or, when
expressed as kcal/kg/day or g protein/kg/day, in males or
females considered separately or combined were not dif-
ferent from normals (Table 2).
Body composition measurements, obtained by stan-
dard manual anthropometric methods, are shown in
Table 3. No maintenance hemodialysis patient or nor-
mal individual manifested edema. There were no signifi-
cant differences in anthropometric measurements in the
maintenance hemodialysis patients vs. the normal con-
trols when the males or females were considered sepa-
rately or when the two genders were combined. However,
the absolute values for the edema-free body weight of the
female maintenance hemodialysis patients were greater
than in the normal women; this was due to one obese
female maintenance hemodialysis patient who weighed
164.1 kg.
The mRNA levels for IGF-IEa, IGF-IEc, IGF-II, IGF-
IR, IGF-IIR, and myostatin in the right vastus lateralis
muscle are shown in Table 4. Because of technical diffi-
culties, myostatin mRNA was assayed in only 44 main-
tenance hemodialysis patients (27 men) and 18 normal
controls (13 men). There was a statistically significant re-
duction in IGF-IEa, IGF-II mRNA, and IGF-IR mRNA
in the MHD patients as compared to the normal con-
trols. There were no significant differences in the mRNA
levels for IGF-IEc, IGF-IIR, or myostatin between the
two groups, although the absolute values for IGF-IEc av-
eraged 32% lower in the maintenance hemodialysis pa-
tients vs. normals.
Most of these differences or lack of differences per-
sisted when the analyses were limited to a single gen-
der (Table 4). Thus, in male and female maintenance
hemodialysis patients, the mRNA levels for IGF-II and
IGF-IR were significantly lower than in the normals of
the same gender. IGF-IEa mRNA was lower than the
normal values in men, but not in women receiving main-
tenance hemodialysis, possibly because the sample size of
the women was smaller. There was no significant differ-
ence in the mRNA for IGF-IEc, IGF-IIR, or myostatin in
either men or women receiving maintenance hemodialy-
sis as compared to the respective normal controls of the
same gender.
Among the patients undergoing maintenance
hemodialysis, the women had greater mRNA levels
for IGF-IIR in their vastus lateralis muscle than did men
(P = 0.018) (Table 4). There were no other significant
differences in gene expression for any of the other
growth factor proteins assessed in men vs. women in
either the maintenance hemodialysis or the normal
control groups.
The five maintenance hemodialysis patients who had
diabetes mellitus showed the same trend in mRNA lev-
els as the nondiabetic maintenance hemodialysis patients
(data not shown) with one exception. The exception was
significantly higher muscle IGF-II mRNA in the diabetic
maintenance hemodialysis patients (12.7 ± 4.8) as com-
pared to the nondiabetic maintenance hemodialysis pa-
tients (6.6 ± 4.5) (P < 0.05). When the 46 maintenance
hemodialysis patients who did not have diabetes melli-
tus were analyzed separately, the identical muscle mR-
NAs were significantly different from the controls as was
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Table 2. Food intake
Maintenance hemodialysis patients Normal controls
Men Women Total Men Women Total
Number of subjects 28 18 46 16 4 20
Energy intake kcal/day 1833 ± 760a,b 2060 ± 933 1922 ± 830 2438 ± 665 1601 ± 136 2271 ± 686
Energy intake kcal/kg/day 27 ± 14 30 ± 13 28 ± 13 34 ± 10 27 ± 6 32 ± 9
Protein intake g/day 75.5 ± 28.2b 72.6 ± 32.1 74.3 ± 29.4b 102.8 ± 52.4 64.0 ± 22.8 95.0 ± 50.0
Protein intake g/kg/day 1.10 ± 0.47 1.14 ± 0.61 1.11 ± 0.52 1.43 ± 0.77 1.12 ± 0.60 1.37 ± 0.73
aMean ± SD.
bSignificantly different from normal subjects of the same gender or from the normal males and females combined, P < 0.05.
Table 3. Body composition by anthropometrya
Maintenance hemodialysis patients Normal controls
Men Women Total Men Women Total
Number 32 19 51 16 5 21
Height cm 168.2 ± 7.7b 159.4 ± 7.6 165.0 ± 8.7 171.4 ± 8.8 161.4 ± 8.9 169.0 ± 9.7
Weight kg 73.1 ± 21.4 71.2 ± 29.6 72.4 ± 24.4 73.2 ± 10.4 61.6 ± 8.5 70.4 ± 11.0
Skinfold thickness
Subscapular mm 17.0 ± 6.9 22.9 ± 14.8 19.2 ± 10.8 18.1 ± 7.2 17.0 ± 7.2 18.4 ± 7.3
Triceps mm 13.4 ± 8.2 21.7 ± 10.5 16.5 ± 9.9 12.5 ± 6.2 18.5 ± 3.1 13.9 ± 6.1
Biceps mm 7.6 ± 5.7 14.0 ± 9.3 9.9 ± 7.8 7.9 ± 4.4 9.1 ± 4.3 8.2 ± 4.3
Mid-arm muscle circumference cm 31.8 ± 5.9 30.8 ± 7.0 31.4 ± 6.3 31.8 ± 2.6 27.2 ± 1.8 30.7 ± 3.1
Mid-calf muscle circumference cm 35.2 ± 4.2 34.0 ± 6.0 34.8 ± 4.9 36.0 ± 2.6 34.2 ± 3.7 35.6 ± 2.9
Mid-thigh muscle circumference cm 47.6 ± 9.1 48.4 ± 6.4 47.9 ± 8.2 49.1 ± 3.3 49.1 ± 5.9 49.1 ± 3.9
% Body fatc 25.3 ± 6.5 32.9 ± 10.0 28.1 ± 8.7 23.6 ± 5.7 32.8 ± 3.0 25.8 ± 6.5
Body mass index kg/m2 26.4 ± 6.9 27.3 ± 9.2 27.4 ± 8.6 24.9 ± 2.9 23.6 ± 2.2 24.0 ± 3.0
aAnthropometry performed by Harbor-UCLA General Clinical Research Center research dieticians. There were no significant differences between male, female or
total maintenance hemodialysis patients vs. the respective normal controls.
bMean ± SD.
cTotal body fat expressed as percent of total body weight.
observed for the entire group of 51 diabetic and nondia-
betic maintenance hemodialysis patients.
IGF-I protein concentrations in the vastus later-
alis muscle were significantly increased in maintenance
hemodialysis patients vs. normal controls (Table 5). Mus-
cle IGF-II protein was not different between the two
groups. Serum IGF-II and TNF-a were significantly
greater in the maintenance hemodialysis patients vs. nor-
mal controls (Table 5). In contrast, there were no signifi-
cant differences in serum IGF-I, CRP, and IL-6 between
the two groups, although values for each of these proteins
tended to be higher in the maintenance hemodialysis pa-
tients (Table 5).
Because a rather large number of variables were mea-
sured in this study, only correlations concerning growth
factors and cytokines that had a regression coefficient
value greater than 0.30 are reported here. In maintenance
hemodialysis patients, muscle mRNA levels for IGF-IEa
were correlated with IGF-IEc (r = 0.385, P = 0.005).
Muscle IGF-II mRNA was correlated with muscle IGF-
IR mRNA (r = 0.321, P = 0.022) and with muscle IGF-II
protein, expressed per mg of wet muscle (r = 0.424, P <
0.002). Muscle IGF-I protein, expressed per lg of muscle
protein, was correlated with IGF-II protein, expressed
per lg muscle protein (r = 0.595, P < 0.001). Muscle
IGF-II protein, expressed per lg of muscle protein, was
correlated with serum IGF-II protein (r = 0.491, P <
0.001) and with serum IGF-I (r = 0.315, P = 0.0244). In
serum, IGF-I was correlated with IGF-II (r = 0.456, P <
0.001). In the maintenance hemodialysis patients, serum
CRP correlated negatively with muscle IGF-IEc mRNA
(r = −0.308, P < 0.05), and serum TNF-a was negatively
correlated with serum IGF-II (r = −0.331, P < 0.03).
In the normal individuals, skeletal muscle IGF-I was
strongly correlated with muscle IGF-II whether ex-
pressed per mg wet muscle weight (r = 0.761, P < 0.001)
or per lg muscle protein (r = 0.689, P < 0.001). Muscle
IGF-I, expressed per lg of muscle protein, correlated in-
versely with IL-6 (r = −0.543, P = 0.02), and serum CRP
correlated positively with IL-6 (r = 0.55, P = 0.018).
Muscle strength and power were significantly reduced
in the maintenance hemodialysis patients as compared to
the normal controls (Fig. 1). There was no difference in
muscle fatigability between the two groups.
DISCUSSION
This study indicates that in vastus lateralis muscle
mRNA levels for some growth factors that promote pro-
tein synthesis and skeletal muscle mass are significantly
decreased in clinically stable, sedentary maintenance
hemodialysis patients as compared to sedentary normal
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Table 4. Growth factor mRNA levels in skeletal muscle
Maintenance
hemodialysis Normal
patients controls P value
IGF-IEa mRNA (×10−4)
Total 16.6 ± 11.9 23.5 ± 9.2 <0.05
Men 15.5 ± 11.4 23.4 ± 9.9 <0.05
Women 18.5 ± 12.8 23.8 ± 7.5 >0.05
IGF-IEc mRNA (×10−5)
Total 6.4 ± 6.1 9.4 ± 10.2 >0.05
Men 5.7 ± 5.2 7.5 ± 5.9 >0.05
Women 7.6 ± 7.3 15.4 ± 18.2 >0.05
IGF-II mRNA (×10−3)
Total 7.2 ± 4.8 12.1 ± 6.9 <0.001
Men 7.5 ± 5.3 11.8 ± 7.2 <0.05
Women 6.7 ± 4.0 13.1 ± 6.3 0.009
IGF-IR mRNA (×10−4)
Total 10.0 ± 4.5 14.9 ± 7.4 <0.001
Men 9.3 ± 4.4 14.3 ± 7.5 0.006
Women 11.1 ± 4.7 17.0 ± 7.5 <0.05
IGF-IIR mRNA (×10−2)
Total 2.67 ± 1.23 2.74 ± 1.27 >0.05
Men 2.28 ± 1.10 2.65 ± 1.40 >0.05
Women 3.22 ± 1.24a 3.01 ± 0.87 >0.05
Myostatin mRNA (×10−4)
Total 20.4 ± 11.4 20.2 ± 8.7 >0.05
Men 21.9 ± 11.8 20.1 ± 9.2 >0.05
Women 18.1 ± 10.9 20.5 ± 8.3 >0.05
Abbreviations are: IGF, insulin-like growth factor; IGF-IR, insulin-like
growth factor receptor.
aSignificantly different from male maintenance hemodialysis patients, P =
0.018.
Table 5. Serum and skeletal muscle Insulin-like growth factor
(IGF)-I, IGF-II, and serum proinflammatory cytokines
Maintenance
hemodialysis Normal
patients controls P value
Serum
IGF-I lg/mL 244 ± 104 (51)a,b 201 ± 64 (21) NS
IGF-II lg/mL 1169 ± 269 (51) 867 ± 296 (21) <0.001
C-reactive protein mg/L 3.65 ± 3.62 (44) 2.45 ± 3.00 (18) NS
Tumor necrosis 3.17 ± 1.15 (44) 1.78 ± 1.48 (18) <0.001
factor a pg/mL
Interleukin-6 pg/mL 4.85 ± 3.95 (44) 3.23 ± 2.21 (18) NS
Muscle
IGF-I ng/mg 131 ± 54 (51) 100 ± 35 (21) <0.05
IGF-II lg/mg 7.88 ± 1.22 (51) 8.24 ± 1.09 (21) NS
aMean ± SD.
bNumber in parentheses indicates sample size.
individuals of similar age, gender, and racial/ethnic char-
acteristics. This reduction was observed for the mRNA
levels for IGF-IEa, IGF-II, and the IGF-IR. In contrast,
the mRNA levels for IGF-IEc, IGF-IIR, and myostatin
were not significantly different between the maintenance
hemodialysis patients and the normal subjects, whether
the data were analyzed separately by gender or with the
two genders combined.
Skeletal muscle IGF-I appears to be important for the
preservation of skeletal muscle architecture and protein
and also for muscle hypertrophy [10]. Circulating IGF-I
appears to have relatively little effect on muscle hypertro-
phy [20], and evidence suggests that most skeletal mus-
cle IGF-I is synthesized in situ [21]. Hence, alterations
in messenger RNA levels for growth factors in skeletal
muscle may affect muscle mass.
Three isoforms of IGF-I are recognized in humans:
IGF-IEa, IGF-IEb, and IGF-IEc. These isoforms are gen-
erated by splice variants of the same IGF-I gene [22].
IGF-IEa and IGF-IEc, the isoforms for which the IGF-
I mRNA was measured in the present study, have been
identified in skeletal muscle. IGF-IEb is found primar-
ily in liver, and it is not known whether it has any ef-
fect on muscle. Thus these reductions in gene expres-
sion for IGF-I (i.e., the IGF-IEa and IGF-IEc isoforms),
IGF-II and IGF-IR may predispose individuals to the
atrophy of skeletal muscle fibers and sarcopenia that
have been described in patients with advanced CRF or
with ESRD who are undergoing maintenance dialysis
therapy [5–7]. In humans, muscle strength is propor-
tional to muscle mass [23], Hence, sarcopenia, engen-
dered in part by decreased mRNA levels for IGF-IEa,
IGF-II and IGF-IR, may be a cause of the decreased
strength described in individuals with advanced CRF
or ESRD [24]. Although IGF-IEc mRNA was not sig-
nificantly reduced in the maintenance hemodialysis pa-
tients, the same trend toward lower mRNA values was
observed for this growth factor as for IGF-IEa mRNA
(Table 4).
The causes for decreased mRNA levels for IGF-IEa,
IGF-II, and IGF-IR in the maintenance hemodialysis pa-
tients are not clear. Growth factors in skeletal muscle may
decrease with age [25], but the ages of the maintenance
hemodialysis patients and normal volunteers were not
different (Table 1). Similarly, the racial/ethnic and gender
distribution of the two groups were similar, and, the same
trend toward reductions in the mRNA for IGF-I, IGF-
II, and IGF-IR was observed in male and female main-
tenance hemodialysis patients considered separately
(Table 4).
States of protein-energy malnutrition (PEM) and
inflammation are commonly present in maintenance
hemodialysis patients [1, 2]. It is possible that these
conditions may have led to a reduction in gene ex-
pression or in mRNA levels in skeletal muscle of
these patients. The maintenance hemodialysis patients
in this study showed a significantly increased serum
TNF-a, and the absolute values for serum CRP and
IL-6 were somewhat greater in these individuals, al-
though the increase was not statistically significant
(Table 5). Moreover, in skeletal muscle of the mainte-
nance hemodialysis patients, serum CRP was negatively
correlated with mRNA levels for IGF-IEc, and TNF-a
was negatively correlated with serum IGF-II.
Reduced nutritional intake might also lead to alter-
ations in the mRNA levels in skeletal muscle for some
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Fig. 1. Leg press strength, extension power and fatigability in sedentary maintenance hemodialysis (MHD) patients (N = 51) and sedentary normal
controls (N = 21) of similar age, gender distribution, and racial/ethnic backgrounds. Brackets indicate standard deviation. Significant difference
between maintenance hemodialysis patients and controls. ∗P = 0.009; †P < 0.001; NS, not significantly different.
growth factors [26, 27], although the literature is some-
what conflictive with regard to the effects of nutrient
restriction or fasting on tissue mRNA levels [26–29].
Moreover, estimates of dietary energy and protein intake
in our maintenance hemodialysis patients, when adjusted
for body size, were not different from the normal levels
(Table 2). However, dietary protein requirements are in-
creased in maintenance hemodialysis patients [30], and
the estimated intakes indicated that many of the mainte-
nance hemodialysis patients were probably ingesting less
energy or protein than is recommended for them by the
National Kidney Foundation K/DOQI Clinical Practice
Guidelines [31]. Whether the evidence for active inflam-
mation or the reductions in energy and/or protein intake,
particularly in the male maintenance hemodialysis pa-
tients, were sufficient to contribute to the lower skeletal
muscle mRNA levels is not known.
The results of the present study also indicated elevated
IGF-I and normal IGF-II levels in skeletal muscle and el-
evated IGF-II and normal IGF-I concentrations in serum
of maintenance hemodialysis patients. It is emphasized
that we were not able to measure the IGF-IEa, IGF-IEb,
or IGF-IEc proteins, and the IGF-I protein concentra-
tions reported refer to mature IGF-I [15]. IGF-I and IGF-
II are largely bound to various binding proteins in both
plasma and solid tissue, including skeletal muscle [32].
The binding proteins may serve several functions, includ-
ing storage of IGF-I and rendering the bound component
of this compound inactive [33]. Therefore, the finding
of elevated IGF-I and normal IGF-II in skeletal muscle
does not necessarily indicate either increased or normal
rates of synthesis or activity of these proteins in skeletal
muscle. Hence, these findings are not inconsistent with
low mRNA levels for these proteins. Studies of cultured
myoblasts indicate that the IGF-II protein may suppress
IGF-II mRNA [34]. Whether increased IGF-I will sup-
press IGF-IEa mRNA in human skeletal muscle is not
known.
It is pertinent that Ding et al [12] found decreased
skeletal muscle IGF-I mRNA and IGF-I protein in rats
with chronic renal insufficiency as compared with pair-
fed, sham-operated control rats. Tonshoff et al [35] also
found that rats with chronic renal insufficiency displayed
reduced hepatic, muscle and lung IGF-I mRNA, and
normal plasma IGF-I concentrations. In contrast to the
present study, Ding et al [12] observed increased IGF-IR
mRNA and IGF-IR number in their rats with chronic
renal insufficiency. Species differences, or the comor-
bidity, inflammation, more advanced renal failure or ef-
fects of the hemodialysis procedure in the maintenance
hemodialysis patients might account for these disparate
findings.
A possible limitation of this study is that the mainte-
nance hemodialysis patients may have been sicker from
comorbid illness and/or they may have been more seden-
tary. The maintenance hemodialysis patients were se-
lected to be clinically stable individuals without active
catabolic illness, and only five of these patients had
noninsulin-requiring diabetes mellitus. The maintenance
hemodialysis patients (but not the normal controls) had
all agreed to participate in an exercise training project,
and were almost certainly a healthier subset of mainte-
nance hemodialysis patients. This may explain why their
nutrient intake and anthropometric measures of body
composition did not indicate a more malnourished sta-
tus than the normal controls (Tables 2 and 3).
Both maintenance hemodialysis patients and normal
controls in this study were selected to be sedentary in-
dividuals, although it is possible that the maintenance
hemodialysis patients might have been less active phys-
ically than the normal control subjects. Individuals un-
dergoing regular dialysis therapy often have markedly
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limited daily physical activity [36]. Since exercise will
increase mRNA levels in vastus lateralis muscle for a
number of these growth factors in maintenance
hemodialysis patients [16], it remains possible that de-
spite our efforts to select normal control subjects with
similar levels of physical activity, a lower level of exer-
cise might have contributed to the lower gene expression
for growth factors in the maintenance hemodialysis pa-
tients. However, the findings that the body weight, total
body fat, fat-free, edema-free mass, and mid-arm mus-
cle circumference, mid-thigh muscle circumference, and
mid-calf muscle circumference were similar in the main-
tenance hemodialysis patients vs. the normal subjects
suggest that there were not great differences in physical
activity between the two groups.
The possibly healthier physical status of the mainte-
nance hemodialysis patients in this study is consistent
with the fact that CRP and IL-6 levels were not differ-
ent from the normal controls and that the maintenance
hemodialysis patients displayed elevated muscle IGF-I
and serum IGF-II levels. It is not unlikely that more mal-
nourished and debilitated maintenance hemodialysis pa-
tients may have even more profound disturbances in the
skeletal muscle mRNA levels for various growth factors.
Finally, whether factors in the uremic milieu of main-
tenance hemodialysis patients may have lowered the
mRNA levels is not known. It should be emphasized that
mRNA levels were only assessed in the right vastus lat-
eralis muscle. It is possible that mRNA levels for these
growth factors in other muscles may not show the same
abnormalities.
In view of the low muscle mRNA levels for IGF-IEa,
IGF-II, and the IGF-IR, it might be questioned why body
composition was similar in the maintenance hemodialy-
sis patients and normal controls. It is possible that the
decreased mRNA levels for growth factors could lead
to a reduction in remodeling of certain functional pro-
teins in the muscle cell which may affect muscle structure,
metabolism and function but not overall muscle mass.
For example, capillary and mitochondria density and the
content or activity of many enzymes may rise or fall in
myocytes in response to various stimuli [37]. In this re-
gard, muscle strength and power were reduced in our
maintenance hemodialysis patients as compared to the
normal controls, notwithstanding the similar anthropo-
metric measurements in the two groups. In addition, fac-
tors independent of mRNA levels may influence protein
synthesis, protein mass, and hence body composition [38].
Also, anthropometry under the best of circumstances is
a rather imprecise measure of muscle mass.
Nonetheless, the findings of this study indicate al-
terations in the molecular processes underlying pro-
tein synthesis in skeletal muscle. It should be empha-
sized that we deliberately chose rather well-nourished
and healthy maintenance hemodialysis patients so that
some of mechanisms underlying skeletal muscle pro-
tein synthesis in CRF patients undergoing maintenance
hemodialysis could be examined independently of such
complicating adverse conditions as malnutrition, super-
imposed illness or muscle atrophy.
The current study has several strengths. It is the first
comparison in patients with advanced CRF undergoing
maintenance hemodialysis vs. normals of the mRNA lev-
els in skeletal muscle for growth factors related to IGF-I,
IGF-II, the IGF-IR, IGF-IIR, and myostatin. The normal
control subjects were selected to have similar character-
istics to the maintenance hemodialysis patients with re-
gard to a number of factors extraneous to renal failure or
maintenance hemodialysis that conceivably might affect
the mRNA levels. In this regard, the similar age, gender
distribution, and approximate level of physical activity
and the lack of acute intercurrent illness or severe co-
morbidity in the maintenance hemodialysis patients and
normal controls were probably particularly important. Fi-
nally, real-time PCR rather than conventional PCR was
used; the former method is considered to be more sensi-
tive and accurate [39]. Further studies would be helpful to
ascertain the causes of these decreased mRNA levels and
whether enhancing these levels would reduce sarcope-
nia and physical disabilities in maintenance hemodialysis
patients.
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